Lucie Nekvindová1,2, Jiří Vencovský2,3, Karel Pavelka2,3, Pavel Horák4,5, Zlatuše Křístková1, Jakub Závada6,7. 1. Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic. 2. Institute of Rheumatology, Na Slupi 4, 128 00, Prague, Czech Republic. 3. Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic. 4. Department of Internal Medicine III - Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. 5. University Hospital, Olomouc, Czech Republic. 6. Institute of Rheumatology, Na Slupi 4, 128 00, Prague, Czech Republic. zavada@revma.cz. 7. Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic. zavada@revma.cz.
Abstract
BACKGROUND: Treat-to-target (T2T) is a widely accepted strategy for patients with rheumatoid arthritis (RA). It recommends attaining a goal of at least low disease activity (LDA) within 6 months; otherwise, the current therapy should be modified. We aimed to investigate whether switching a first-line targeted therapy (TT) in patients not reaching LDA within 6 months leads to a higher probability of meeting LDA at the 12-month visit in daily clinical practice using data from Czech registry ATTRA. METHODS: We included patients with RA starting the first-line TT from 1 January 2012 to 31 January 2017 with at least 1-year follow-up. We created four mutually exclusive cohorts based on (1) switching to another TT within the first year and (2) reaching a treatment target (DAS28-ESR ≤ 3.2) at the 6-month visit. The primary outcome was the comparison of odds for reaching remission (REM) or LDA at the 12-month visit between patients switching and not switching TT after not reaching treatment target at 6 months. Before using logistic regression to estimate the odds ratio, we employed the propensity score to match patients at the 6-month visit. RESULTS: A total of 1275 patients were eligible for the analysis. Sixty-two patients switched within the first 5 months of the treatment before evaluating treatment response at the 6-month visit (C1); 598 patients reached the treatment target within 6 months of therapy (C2); 124 patients did not reach treatment response at 6-month visit and switched to another therapy (C3), and 491 patients continued with the same treatment despite not reaching LDA at the 6-month visit (C4). We matched 75 patients from cohort C3 and 75 patients from C4 using the propensity score. Patients following the T2T principle (C3) showed 2.8 (95% CI 1.4-5.8; p = 0.005) times increased likelihood of achieving REM/LDA at the 12-month visit compared to patients not following the T2T strategy (C4). CONCLUSIONS: In daily clinical practice, the application of the T2T strategy is underused. Switching TT after not reaching REM/LDA within the first 6 months leads to a higher probability of achieving REM/LDA in RA patients at the 12-month visit.
BACKGROUND: Treat-to-target (T2T) is a widely accepted strategy for patients with rheumatoid arthritis (RA). It recommends attaining a goal of at least low disease activity (LDA) within 6 months; otherwise, the current therapy should be modified. We aimed to investigate whether switching a first-line targeted therapy (TT) in patients not reaching LDA within 6 months leads to a higher probability of meeting LDA at the 12-month visit in daily clinical practice using data from Czech registry ATTRA. METHODS: We included patients with RA starting the first-line TT from 1 January 2012 to 31 January 2017 with at least 1-year follow-up. We created four mutually exclusive cohorts based on (1) switching to another TT within the first year and (2) reaching a treatment target (DAS28-ESR ≤ 3.2) at the 6-month visit. The primary outcome was the comparison of odds for reaching remission (REM) or LDA at the 12-month visit between patients switching and not switching TT after not reaching treatment target at 6 months. Before using logistic regression to estimate the odds ratio, we employed the propensity score to match patients at the 6-month visit. RESULTS: A total of 1275 patients were eligible for the analysis. Sixty-two patients switched within the first 5 months of the treatment before evaluating treatment response at the 6-month visit (C1); 598 patients reached the treatment target within 6 months of therapy (C2); 124 patients did not reach treatment response at 6-month visit and switched to another therapy (C3), and 491 patients continued with the same treatment despite not reaching LDA at the 6-month visit (C4). We matched 75 patients from cohort C3 and 75 patients from C4 using the propensity score. Patients following the T2T principle (C3) showed 2.8 (95% CI 1.4-5.8; p = 0.005) times increased likelihood of achieving REM/LDA at the 12-month visit compared to patients not following the T2T strategy (C4). CONCLUSIONS: In daily clinical practice, the application of the T2T strategy is underused. Switching TT after not reaching REM/LDA within the first 6 months leads to a higher probability of achieving REM/LDA in RApatients at the 12-month visit.
Authors: M Vermeer; H H Kuper; H J Bernelot Moens; K W Drossaers-Bakker; A E van der Bijl; P L C M van Riel; M A F J van de Laar Journal: Arthritis Care Res (Hoboken) Date: 2013-08 Impact factor: 4.794
Authors: Lydia G Schipper; Laura T C van Hulst; Richard Grol; Piet L C M van Riel; Marlies E J L Hulscher; Jaap Fransen Journal: Rheumatology (Oxford) Date: 2010-07-29 Impact factor: 7.580
Authors: Lydia G Schipper; Marloes Vermeer; Hillechiena H Kuper; Monique O Hoekstra; Cees J Haagsma; Alfons A Den Broeder; Piet van Riel; Jaap Fransen; Mart A F J van de Laar Journal: Ann Rheum Dis Date: 2011-12-30 Impact factor: 19.103
Authors: J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell Journal: Rheumatology (Oxford) Date: 2003-02 Impact factor: 7.580
Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; P J S M Kerstens; M M J Nielen; K Vos; D van Schaardenburg; I Speyer; P E H Seys; F C Breedveld; C F Allaart; B A C Dijkmans Journal: Ann Rheum Dis Date: 2010-01 Impact factor: 19.103
Authors: Dimitrios A Pappas; Robert A Gerber; Heather J Litman; David Gruben; Jamie Geier; Winnie D Hua; Connie Chen; Youfu Li; Joel M Kremer; John S Andrews; Jeffrey A Bourret Journal: Am Health Drug Benefits Date: 2018-05
Authors: L M M Steunebrink; G A Versteeg; H E Vonkeman; P M Ten Klooster; H H Kuper; T R Zijlstra; P L C M van Riel; M A F J van de Laar Journal: Arthritis Res Ther Date: 2016-03-08 Impact factor: 5.156
Authors: G A Versteeg; L M M Steunebrink; H E Vonkeman; P M Ten Klooster; A E van der Bijl; M A F J van de Laar Journal: Clin Rheumatol Date: 2018-02-01 Impact factor: 2.980